Global Epilepsy Drugs Market

Epilepsy Drugs Comprehensive Study by Type (Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Treatment Drugs (First Generation Drugs, Second Generation Drugs, Second Generation Drugs), End – User (Male, Female), Symptoms (Temporary confusion, A staring spell, Uncontrollable jerking movements of the arms and legs, Loss of consciousness or awareness, Psychic symptoms such as fear, anxiety or deja vu) Players and Region - Global Market Outlook to 2029

Epilepsy Drugs Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Epilepsy Drugs are used to treat people who are suffering from epilepsy diseases, it is a central nervous system disorder in the brain by which brain activities sometimes become abnormal. These activities are able to cause seizers or unusual behaviors to the patients. The symptoms of these diseases caused brain malfunction, tumors and in women, it majorly can cause a high risk of pregnancies. So to prevent all these consequences epilepsy drugs are used to cured patients and all these circumstances are also driving the market for these drugs.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories (United States), GlaxoSmithKline Plc (United Kingdom), UCB (Europe), Cephalon, Inc. (United States), Johnson & Johnson (United States), Pfizer (United States), Novartis AG (Switzerland), AbbVie Inc. (United States), Sunovion Pharmaceuticals (United States) and Bausch Health (Canada)


Segment Analysis
AMA Research have segmented the market of Global Epilepsy Drugs market by Type, Application and Region.

On the basis of geography, the market of Epilepsy Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Trend
Increase in Epilepsy Management Costs and Acceptance in Use of Immunotherapy and Immunomodulators

Market Drivers
Developments in Understanding of Epilepsy Pathology, Rising Road Traffic Injuries Coupled with Higher Incidence of Birth-Related Injuries and Rising Incidents of Neurological Disorders

Opportunities
Campaigning Of Several Programs Related to the Treatment of Seizures in Epileptic Patients, Growing Government Funding and Drugs Reimbursement Options in European & American Countries and Growing Screening of Patients, Penetration, and Availability of Drugs in Developing Countries

Restraints
  • High Cost of Patented Drugs and Low Accessibility to Epilepsy Drugs in Low and Middle-Income Countries
  • High Cost of Antiepileptic Drugs


In addition to the aforementioned factor, Developments in Understanding of Epilepsy Pathology is expected to propel the growth of the market over the forecast period.

The key Players profiled in the study are Abbott Laboratories (United States), GlaxoSmithKline Plc (United Kingdom), UCB (Europe), Cephalon, Inc. (United States), Johnson & Johnson (United States), Pfizer (United States), Novartis AG (Switzerland), AbbVie Inc. (United States), Sunovion Pharmaceuticals (United States) and Bausch Health (Canada). A lot of Global players are profiled in the research study indicating a strong market dependence.

Report Objectives / Segmentation Covered

By Type
  • Vimpat (Lacosamide)
  • Keppra (Levetiracetam)
  • Sabril (Vigabatrin)
  • Onfi (Clobazam)
  • Fycompa
  • Briviact (Brivaracetam)
  • Epidiolex
  • Cenobamate (YKP3089)
By Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Treatment Drugs
  • First Generation Drugs
  • Second Generation Drugs
  • Second Generation Drugs

By End – User
  • Male
  • Female

By Symptoms
  • Temporary confusion
  • A staring spell
  • Uncontrollable jerking movements of the arms and legs
  • Loss of consciousness or awareness
  • Psychic symptoms such as fear, anxiety or deja vu

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Developments in Understanding of Epilepsy Pathology
      • 3.2.2. Rising Road Traffic Injuries Coupled with Higher Incidence of Birth-Related Injuries
      • 3.2.3. Rising Incidents of Neurological Disorders
    • 3.3. Market Challenges
      • 3.3.1. Issue Related to Low Safety Profile of Antiepilepsy Drugs
    • 3.4. Market Trends
      • 3.4.1. Increase in Epilepsy Management Costs
      • 3.4.2. Acceptance in Use of Immunotherapy and Immunomodulators
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Epilepsy Drugs, by Type, Application, Treatment Drugs, End – User, Symptoms and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Epilepsy Drugs (Value)
      • 5.2.1. Global Epilepsy Drugs by: Type (Value)
        • 5.2.1.1. Vimpat (Lacosamide)
        • 5.2.1.2. Keppra (Levetiracetam)
        • 5.2.1.3. Sabril (Vigabatrin)
        • 5.2.1.4. Onfi (Clobazam)
        • 5.2.1.5. Fycompa
        • 5.2.1.6. Briviact (Brivaracetam)
        • 5.2.1.7. Epidiolex
        • 5.2.1.8. Cenobamate (YKP3089)
      • 5.2.2. Global Epilepsy Drugs by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Epilepsy Drugs by: Treatment Drugs (Value)
        • 5.2.3.1. First Generation Drugs
        • 5.2.3.2. Second Generation Drugs
        • 5.2.3.3. Second Generation Drugs
      • 5.2.4. Global Epilepsy Drugs by: End – User (Value)
        • 5.2.4.1. Male
        • 5.2.4.2. Female
      • 5.2.5. Global Epilepsy Drugs by: Symptoms (Value)
        • 5.2.5.1. Temporary confusion
        • 5.2.5.2. A staring spell
        • 5.2.5.3. Uncontrollable jerking movements of the arms and legs
        • 5.2.5.4. Loss of consciousness or awareness
        • 5.2.5.5. Psychic symptoms such as fear, anxiety or deja vu
      • 5.2.6. Global Epilepsy Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Epilepsy Drugs (Volume)
      • 5.3.1. Global Epilepsy Drugs by: Type (Volume)
        • 5.3.1.1. Vimpat (Lacosamide)
        • 5.3.1.2. Keppra (Levetiracetam)
        • 5.3.1.3. Sabril (Vigabatrin)
        • 5.3.1.4. Onfi (Clobazam)
        • 5.3.1.5. Fycompa
        • 5.3.1.6. Briviact (Brivaracetam)
        • 5.3.1.7. Epidiolex
        • 5.3.1.8. Cenobamate (YKP3089)
      • 5.3.2. Global Epilepsy Drugs by: Application (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Retail Pharmacies
        • 5.3.2.3. Online Pharmacies
      • 5.3.3. Global Epilepsy Drugs by: Treatment Drugs (Volume)
        • 5.3.3.1. First Generation Drugs
        • 5.3.3.2. Second Generation Drugs
        • 5.3.3.3. Second Generation Drugs
      • 5.3.4. Global Epilepsy Drugs by: End – User (Volume)
        • 5.3.4.1. Male
        • 5.3.4.2. Female
      • 5.3.5. Global Epilepsy Drugs by: Symptoms (Volume)
        • 5.3.5.1. Temporary confusion
        • 5.3.5.2. A staring spell
        • 5.3.5.3. Uncontrollable jerking movements of the arms and legs
        • 5.3.5.4. Loss of consciousness or awareness
        • 5.3.5.5. Psychic symptoms such as fear, anxiety or deja vu
      • 5.3.6. Global Epilepsy Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Epilepsy Drugs (Price)
      • 5.4.1. Global Epilepsy Drugs by: Type (Price)
  • 6. Epilepsy Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. UCB (Europe)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cephalon, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sunovion Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bausch Health (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Epilepsy Drugs Sale, by Type, Application, Treatment Drugs, End – User, Symptoms and Region (value, volume and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Epilepsy Drugs (Value)
      • 7.2.1. Global Epilepsy Drugs by: Type (Value)
        • 7.2.1.1. Vimpat (Lacosamide)
        • 7.2.1.2. Keppra (Levetiracetam)
        • 7.2.1.3. Sabril (Vigabatrin)
        • 7.2.1.4. Onfi (Clobazam)
        • 7.2.1.5. Fycompa
        • 7.2.1.6. Briviact (Brivaracetam)
        • 7.2.1.7. Epidiolex
        • 7.2.1.8. Cenobamate (YKP3089)
      • 7.2.2. Global Epilepsy Drugs by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Epilepsy Drugs by: Treatment Drugs (Value)
        • 7.2.3.1. First Generation Drugs
        • 7.2.3.2. Second Generation Drugs
        • 7.2.3.3. Second Generation Drugs
      • 7.2.4. Global Epilepsy Drugs by: End – User (Value)
        • 7.2.4.1. Male
        • 7.2.4.2. Female
      • 7.2.5. Global Epilepsy Drugs by: Symptoms (Value)
        • 7.2.5.1. Temporary confusion
        • 7.2.5.2. A staring spell
        • 7.2.5.3. Uncontrollable jerking movements of the arms and legs
        • 7.2.5.4. Loss of consciousness or awareness
        • 7.2.5.5. Psychic symptoms such as fear, anxiety or deja vu
      • 7.2.6. Global Epilepsy Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Epilepsy Drugs (Volume)
      • 7.3.1. Global Epilepsy Drugs by: Type (Volume)
        • 7.3.1.1. Vimpat (Lacosamide)
        • 7.3.1.2. Keppra (Levetiracetam)
        • 7.3.1.3. Sabril (Vigabatrin)
        • 7.3.1.4. Onfi (Clobazam)
        • 7.3.1.5. Fycompa
        • 7.3.1.6. Briviact (Brivaracetam)
        • 7.3.1.7. Epidiolex
        • 7.3.1.8. Cenobamate (YKP3089)
      • 7.3.2. Global Epilepsy Drugs by: Application (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Retail Pharmacies
        • 7.3.2.3. Online Pharmacies
      • 7.3.3. Global Epilepsy Drugs by: Treatment Drugs (Volume)
        • 7.3.3.1. First Generation Drugs
        • 7.3.3.2. Second Generation Drugs
        • 7.3.3.3. Second Generation Drugs
      • 7.3.4. Global Epilepsy Drugs by: End – User (Volume)
        • 7.3.4.1. Male
        • 7.3.4.2. Female
      • 7.3.5. Global Epilepsy Drugs by: Symptoms (Volume)
        • 7.3.5.1. Temporary confusion
        • 7.3.5.2. A staring spell
        • 7.3.5.3. Uncontrollable jerking movements of the arms and legs
        • 7.3.5.4. Loss of consciousness or awareness
        • 7.3.5.5. Psychic symptoms such as fear, anxiety or deja vu
      • 7.3.6. Global Epilepsy Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Epilepsy Drugs (Price)
      • 7.4.1. Global Epilepsy Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Epilepsy Drugs: by Type(USD Million)
  • Table 2. Epilepsy Drugs Vimpat (Lacosamide) , by Region USD Million (2018-2023)
  • Table 3. Epilepsy Drugs Keppra (Levetiracetam) , by Region USD Million (2018-2023)
  • Table 4. Epilepsy Drugs Sabril (Vigabatrin) , by Region USD Million (2018-2023)
  • Table 5. Epilepsy Drugs Onfi (Clobazam) , by Region USD Million (2018-2023)
  • Table 6. Epilepsy Drugs Fycompa , by Region USD Million (2018-2023)
  • Table 7. Epilepsy Drugs Briviact (Brivaracetam) , by Region USD Million (2018-2023)
  • Table 8. Epilepsy Drugs Epidiolex , by Region USD Million (2018-2023)
  • Table 9. Epilepsy Drugs Cenobamate (YKP3089) , by Region USD Million (2018-2023)
  • Table 10. Epilepsy Drugs: by Application(USD Million)
  • Table 11. Epilepsy Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Epilepsy Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Epilepsy Drugs Online Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Epilepsy Drugs: by Treatment Drugs(USD Million)
  • Table 15. Epilepsy Drugs First Generation Drugs , by Region USD Million (2018-2023)
  • Table 16. Epilepsy Drugs Second Generation Drugs , by Region USD Million (2018-2023)
  • Table 17. Epilepsy Drugs Second Generation Drugs , by Region USD Million (2018-2023)
  • Table 18. Epilepsy Drugs: by End – User(USD Million)
  • Table 19. Epilepsy Drugs Male , by Region USD Million (2018-2023)
  • Table 20. Epilepsy Drugs Female , by Region USD Million (2018-2023)
  • Table 21. Epilepsy Drugs: by Symptoms(USD Million)
  • Table 22. Epilepsy Drugs Temporary confusion , by Region USD Million (2018-2023)
  • Table 23. Epilepsy Drugs A staring spell , by Region USD Million (2018-2023)
  • Table 24. Epilepsy Drugs Uncontrollable jerking movements of the arms and legs , by Region USD Million (2018-2023)
  • Table 25. Epilepsy Drugs Loss of consciousness or awareness , by Region USD Million (2018-2023)
  • Table 26. Epilepsy Drugs Psychic symptoms such as fear, anxiety or deja vu , by Region USD Million (2018-2023)
  • Table 27. South America Epilepsy Drugs, by Country USD Million (2018-2023)
  • Table 28. South America Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 29. South America Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 30. South America Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 31. South America Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 32. South America Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 33. Brazil Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 34. Brazil Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 35. Brazil Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 36. Brazil Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 37. Brazil Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 38. Argentina Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 39. Argentina Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 40. Argentina Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 41. Argentina Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 42. Argentina Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 43. Rest of South America Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 44. Rest of South America Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 45. Rest of South America Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 46. Rest of South America Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 47. Rest of South America Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 48. Asia Pacific Epilepsy Drugs, by Country USD Million (2018-2023)
  • Table 49. Asia Pacific Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 50. Asia Pacific Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 51. Asia Pacific Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 52. Asia Pacific Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 53. Asia Pacific Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 54. China Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 55. China Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 56. China Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 57. China Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 58. China Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 59. Japan Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 60. Japan Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 61. Japan Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 62. Japan Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 63. Japan Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 64. India Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 65. India Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 66. India Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 67. India Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 68. India Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 69. South Korea Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 70. South Korea Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 71. South Korea Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 72. South Korea Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 73. South Korea Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 74. Taiwan Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 75. Taiwan Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 76. Taiwan Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 77. Taiwan Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 78. Taiwan Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 79. Australia Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 80. Australia Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 81. Australia Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 82. Australia Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 83. Australia Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 89. Europe Epilepsy Drugs, by Country USD Million (2018-2023)
  • Table 90. Europe Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 91. Europe Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 92. Europe Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 93. Europe Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 94. Europe Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 95. Germany Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 96. Germany Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 97. Germany Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 98. Germany Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 99. Germany Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 100. France Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 101. France Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 102. France Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 103. France Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 104. France Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 105. Italy Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 106. Italy Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 107. Italy Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 108. Italy Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 109. Italy Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 110. United Kingdom Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 111. United Kingdom Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 112. United Kingdom Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 113. United Kingdom Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 114. United Kingdom Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 115. Netherlands Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 116. Netherlands Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 117. Netherlands Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 118. Netherlands Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 119. Netherlands Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 120. Rest of Europe Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 121. Rest of Europe Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 122. Rest of Europe Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 123. Rest of Europe Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 124. Rest of Europe Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 125. MEA Epilepsy Drugs, by Country USD Million (2018-2023)
  • Table 126. MEA Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 127. MEA Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 128. MEA Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 129. MEA Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 130. MEA Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 131. Middle East Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 132. Middle East Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 133. Middle East Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 134. Middle East Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 135. Middle East Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 136. Africa Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 137. Africa Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 138. Africa Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 139. Africa Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 140. Africa Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 141. North America Epilepsy Drugs, by Country USD Million (2018-2023)
  • Table 142. North America Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 143. North America Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 144. North America Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 145. North America Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 146. North America Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 147. United States Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 148. United States Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 149. United States Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 150. United States Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 151. United States Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 152. Canada Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 153. Canada Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 154. Canada Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 155. Canada Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 156. Canada Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 157. Mexico Epilepsy Drugs, by Type USD Million (2018-2023)
  • Table 158. Mexico Epilepsy Drugs, by Application USD Million (2018-2023)
  • Table 159. Mexico Epilepsy Drugs, by Treatment Drugs USD Million (2018-2023)
  • Table 160. Mexico Epilepsy Drugs, by End – User USD Million (2018-2023)
  • Table 161. Mexico Epilepsy Drugs, by Symptoms USD Million (2018-2023)
  • Table 162. Epilepsy Drugs Sales: by Type(unit)
  • Table 163. Epilepsy Drugs Sales Vimpat (Lacosamide) , by Region unit (2018-2023)
  • Table 164. Epilepsy Drugs Sales Keppra (Levetiracetam) , by Region unit (2018-2023)
  • Table 165. Epilepsy Drugs Sales Sabril (Vigabatrin) , by Region unit (2018-2023)
  • Table 166. Epilepsy Drugs Sales Onfi (Clobazam) , by Region unit (2018-2023)
  • Table 167. Epilepsy Drugs Sales Fycompa , by Region unit (2018-2023)
  • Table 168. Epilepsy Drugs Sales Briviact (Brivaracetam) , by Region unit (2018-2023)
  • Table 169. Epilepsy Drugs Sales Epidiolex , by Region unit (2018-2023)
  • Table 170. Epilepsy Drugs Sales Cenobamate (YKP3089) , by Region unit (2018-2023)
  • Table 171. Epilepsy Drugs Sales: by Application(unit)
  • Table 172. Epilepsy Drugs Sales Hospital Pharmacies , by Region unit (2018-2023)
  • Table 173. Epilepsy Drugs Sales Retail Pharmacies , by Region unit (2018-2023)
  • Table 174. Epilepsy Drugs Sales Online Pharmacies , by Region unit (2018-2023)
  • Table 175. Epilepsy Drugs Sales: by Treatment Drugs(unit)
  • Table 176. Epilepsy Drugs Sales First Generation Drugs , by Region unit (2018-2023)
  • Table 177. Epilepsy Drugs Sales Second Generation Drugs , by Region unit (2018-2023)
  • Table 178. Epilepsy Drugs Sales Second Generation Drugs , by Region unit (2018-2023)
  • Table 179. Epilepsy Drugs Sales: by End – User(unit)
  • Table 180. Epilepsy Drugs Sales Male , by Region unit (2018-2023)
  • Table 181. Epilepsy Drugs Sales Female , by Region unit (2018-2023)
  • Table 182. Epilepsy Drugs Sales: by Symptoms(unit)
  • Table 183. Epilepsy Drugs Sales Temporary confusion , by Region unit (2018-2023)
  • Table 184. Epilepsy Drugs Sales A staring spell , by Region unit (2018-2023)
  • Table 185. Epilepsy Drugs Sales Uncontrollable jerking movements of the arms and legs , by Region unit (2018-2023)
  • Table 186. Epilepsy Drugs Sales Loss of consciousness or awareness , by Region unit (2018-2023)
  • Table 187. Epilepsy Drugs Sales Psychic symptoms such as fear, anxiety or deja vu , by Region unit (2018-2023)
  • Table 188. South America Epilepsy Drugs Sales, by Country unit (2018-2023)
  • Table 189. South America Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 190. South America Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 191. South America Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 192. South America Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 193. South America Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 194. Brazil Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 195. Brazil Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 196. Brazil Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 197. Brazil Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 198. Brazil Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 199. Argentina Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 200. Argentina Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 201. Argentina Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 202. Argentina Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 203. Argentina Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 204. Rest of South America Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 205. Rest of South America Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 206. Rest of South America Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 207. Rest of South America Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 208. Rest of South America Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 209. Asia Pacific Epilepsy Drugs Sales, by Country unit (2018-2023)
  • Table 210. Asia Pacific Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 211. Asia Pacific Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 212. Asia Pacific Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 213. Asia Pacific Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 214. Asia Pacific Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 215. China Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 216. China Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 217. China Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 218. China Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 219. China Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 220. Japan Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 221. Japan Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 222. Japan Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 223. Japan Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 224. Japan Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 225. India Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 226. India Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 227. India Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 228. India Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 229. India Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 230. South Korea Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 231. South Korea Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 232. South Korea Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 233. South Korea Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 234. South Korea Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 235. Taiwan Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 236. Taiwan Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 237. Taiwan Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 238. Taiwan Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 239. Taiwan Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 240. Australia Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 241. Australia Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 242. Australia Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 243. Australia Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 244. Australia Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 245. Rest of Asia-Pacific Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 246. Rest of Asia-Pacific Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 247. Rest of Asia-Pacific Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 248. Rest of Asia-Pacific Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 249. Rest of Asia-Pacific Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 250. Europe Epilepsy Drugs Sales, by Country unit (2018-2023)
  • Table 251. Europe Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 252. Europe Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 253. Europe Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 254. Europe Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 255. Europe Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 256. Germany Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 257. Germany Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 258. Germany Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 259. Germany Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 260. Germany Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 261. France Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 262. France Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 263. France Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 264. France Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 265. France Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 266. Italy Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 267. Italy Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 268. Italy Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 269. Italy Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 270. Italy Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 271. United Kingdom Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 272. United Kingdom Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 273. United Kingdom Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 274. United Kingdom Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 275. United Kingdom Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 276. Netherlands Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 277. Netherlands Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 278. Netherlands Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 279. Netherlands Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 280. Netherlands Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 281. Rest of Europe Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 282. Rest of Europe Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 283. Rest of Europe Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 284. Rest of Europe Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 285. Rest of Europe Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 286. MEA Epilepsy Drugs Sales, by Country unit (2018-2023)
  • Table 287. MEA Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 288. MEA Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 289. MEA Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 290. MEA Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 291. MEA Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 292. Middle East Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 293. Middle East Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 294. Middle East Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 295. Middle East Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 296. Middle East Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 297. Africa Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 298. Africa Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 299. Africa Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 300. Africa Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 301. Africa Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 302. North America Epilepsy Drugs Sales, by Country unit (2018-2023)
  • Table 303. North America Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 304. North America Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 305. North America Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 306. North America Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 307. North America Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 308. United States Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 309. United States Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 310. United States Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 311. United States Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 312. United States Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 313. Canada Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 314. Canada Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 315. Canada Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 316. Canada Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 317. Canada Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 318. Mexico Epilepsy Drugs Sales, by Type unit (2018-2023)
  • Table 319. Mexico Epilepsy Drugs Sales, by Application unit (2018-2023)
  • Table 320. Mexico Epilepsy Drugs Sales, by Treatment Drugs unit (2018-2023)
  • Table 321. Mexico Epilepsy Drugs Sales, by End – User unit (2018-2023)
  • Table 322. Mexico Epilepsy Drugs Sales, by Symptoms unit (2018-2023)
  • Table 323. Epilepsy Drugs: by Type(USD/Units)
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Epilepsy Drugs: by Type(USD Million)
  • Table 335. Epilepsy Drugs Vimpat (Lacosamide) , by Region USD Million (2024-2029)
  • Table 336. Epilepsy Drugs Keppra (Levetiracetam) , by Region USD Million (2024-2029)
  • Table 337. Epilepsy Drugs Sabril (Vigabatrin) , by Region USD Million (2024-2029)
  • Table 338. Epilepsy Drugs Onfi (Clobazam) , by Region USD Million (2024-2029)
  • Table 339. Epilepsy Drugs Fycompa , by Region USD Million (2024-2029)
  • Table 340. Epilepsy Drugs Briviact (Brivaracetam) , by Region USD Million (2024-2029)
  • Table 341. Epilepsy Drugs Epidiolex , by Region USD Million (2024-2029)
  • Table 342. Epilepsy Drugs Cenobamate (YKP3089) , by Region USD Million (2024-2029)
  • Table 343. Epilepsy Drugs: by Application(USD Million)
  • Table 344. Epilepsy Drugs Hospital Pharmacies , by Region USD Million (2024-2029)
  • Table 345. Epilepsy Drugs Retail Pharmacies , by Region USD Million (2024-2029)
  • Table 346. Epilepsy Drugs Online Pharmacies , by Region USD Million (2024-2029)
  • Table 347. Epilepsy Drugs: by Treatment Drugs(USD Million)
  • Table 348. Epilepsy Drugs First Generation Drugs , by Region USD Million (2024-2029)
  • Table 349. Epilepsy Drugs Second Generation Drugs , by Region USD Million (2024-2029)
  • Table 350. Epilepsy Drugs Second Generation Drugs , by Region USD Million (2024-2029)
  • Table 351. Epilepsy Drugs: by End – User(USD Million)
  • Table 352. Epilepsy Drugs Male , by Region USD Million (2024-2029)
  • Table 353. Epilepsy Drugs Female , by Region USD Million (2024-2029)
  • Table 354. Epilepsy Drugs: by Symptoms(USD Million)
  • Table 355. Epilepsy Drugs Temporary confusion , by Region USD Million (2024-2029)
  • Table 356. Epilepsy Drugs A staring spell , by Region USD Million (2024-2029)
  • Table 357. Epilepsy Drugs Uncontrollable jerking movements of the arms and legs , by Region USD Million (2024-2029)
  • Table 358. Epilepsy Drugs Loss of consciousness or awareness , by Region USD Million (2024-2029)
  • Table 359. Epilepsy Drugs Psychic symptoms such as fear, anxiety or deja vu , by Region USD Million (2024-2029)
  • Table 360. South America Epilepsy Drugs, by Country USD Million (2024-2029)
  • Table 361. South America Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 362. South America Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 363. South America Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 364. South America Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 365. South America Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 366. Brazil Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 367. Brazil Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 368. Brazil Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 369. Brazil Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 370. Brazil Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 371. Argentina Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 372. Argentina Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 373. Argentina Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 374. Argentina Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 375. Argentina Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 376. Rest of South America Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 377. Rest of South America Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 378. Rest of South America Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 379. Rest of South America Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 380. Rest of South America Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 381. Asia Pacific Epilepsy Drugs, by Country USD Million (2024-2029)
  • Table 382. Asia Pacific Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 383. Asia Pacific Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 384. Asia Pacific Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 385. Asia Pacific Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 386. Asia Pacific Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 387. China Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 388. China Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 389. China Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 390. China Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 391. China Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 392. Japan Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 393. Japan Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 394. Japan Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 395. Japan Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 396. Japan Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 397. India Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 398. India Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 399. India Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 400. India Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 401. India Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 402. South Korea Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 403. South Korea Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 404. South Korea Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 405. South Korea Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 406. South Korea Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 407. Taiwan Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 408. Taiwan Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 409. Taiwan Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 410. Taiwan Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 411. Taiwan Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 412. Australia Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 413. Australia Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 414. Australia Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 415. Australia Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 416. Australia Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 417. Rest of Asia-Pacific Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 418. Rest of Asia-Pacific Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 419. Rest of Asia-Pacific Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 420. Rest of Asia-Pacific Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 421. Rest of Asia-Pacific Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 422. Europe Epilepsy Drugs, by Country USD Million (2024-2029)
  • Table 423. Europe Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 424. Europe Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 425. Europe Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 426. Europe Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 427. Europe Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 428. Germany Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 429. Germany Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 430. Germany Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 431. Germany Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 432. Germany Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 433. France Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 434. France Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 435. France Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 436. France Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 437. France Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 438. Italy Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 439. Italy Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 440. Italy Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 441. Italy Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 442. Italy Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 443. United Kingdom Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 444. United Kingdom Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 445. United Kingdom Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 446. United Kingdom Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 447. United Kingdom Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 448. Netherlands Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 449. Netherlands Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 450. Netherlands Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 451. Netherlands Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 452. Netherlands Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 453. Rest of Europe Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 454. Rest of Europe Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 455. Rest of Europe Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 456. Rest of Europe Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 457. Rest of Europe Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 458. MEA Epilepsy Drugs, by Country USD Million (2024-2029)
  • Table 459. MEA Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 460. MEA Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 461. MEA Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 462. MEA Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 463. MEA Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 464. Middle East Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 465. Middle East Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 466. Middle East Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 467. Middle East Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 468. Middle East Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 469. Africa Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 470. Africa Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 471. Africa Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 472. Africa Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 473. Africa Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 474. North America Epilepsy Drugs, by Country USD Million (2024-2029)
  • Table 475. North America Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 476. North America Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 477. North America Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 478. North America Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 479. North America Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 480. United States Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 481. United States Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 482. United States Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 483. United States Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 484. United States Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 485. Canada Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 486. Canada Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 487. Canada Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 488. Canada Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 489. Canada Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 490. Mexico Epilepsy Drugs, by Type USD Million (2024-2029)
  • Table 491. Mexico Epilepsy Drugs, by Application USD Million (2024-2029)
  • Table 492. Mexico Epilepsy Drugs, by Treatment Drugs USD Million (2024-2029)
  • Table 493. Mexico Epilepsy Drugs, by End – User USD Million (2024-2029)
  • Table 494. Mexico Epilepsy Drugs, by Symptoms USD Million (2024-2029)
  • Table 495. Epilepsy Drugs Sales: by Type(unit)
  • Table 496. Epilepsy Drugs Sales Vimpat (Lacosamide) , by Region unit (2024-2029)
  • Table 497. Epilepsy Drugs Sales Keppra (Levetiracetam) , by Region unit (2024-2029)
  • Table 498. Epilepsy Drugs Sales Sabril (Vigabatrin) , by Region unit (2024-2029)
  • Table 499. Epilepsy Drugs Sales Onfi (Clobazam) , by Region unit (2024-2029)
  • Table 500. Epilepsy Drugs Sales Fycompa , by Region unit (2024-2029)
  • Table 501. Epilepsy Drugs Sales Briviact (Brivaracetam) , by Region unit (2024-2029)
  • Table 502. Epilepsy Drugs Sales Epidiolex , by Region unit (2024-2029)
  • Table 503. Epilepsy Drugs Sales Cenobamate (YKP3089) , by Region unit (2024-2029)
  • Table 504. Epilepsy Drugs Sales: by Application(unit)
  • Table 505. Epilepsy Drugs Sales Hospital Pharmacies , by Region unit (2024-2029)
  • Table 506. Epilepsy Drugs Sales Retail Pharmacies , by Region unit (2024-2029)
  • Table 507. Epilepsy Drugs Sales Online Pharmacies , by Region unit (2024-2029)
  • Table 508. Epilepsy Drugs Sales: by Treatment Drugs(unit)
  • Table 509. Epilepsy Drugs Sales First Generation Drugs , by Region unit (2024-2029)
  • Table 510. Epilepsy Drugs Sales Second Generation Drugs , by Region unit (2024-2029)
  • Table 511. Epilepsy Drugs Sales Second Generation Drugs , by Region unit (2024-2029)
  • Table 512. Epilepsy Drugs Sales: by End – User(unit)
  • Table 513. Epilepsy Drugs Sales Male , by Region unit (2024-2029)
  • Table 514. Epilepsy Drugs Sales Female , by Region unit (2024-2029)
  • Table 515. Epilepsy Drugs Sales: by Symptoms(unit)
  • Table 516. Epilepsy Drugs Sales Temporary confusion , by Region unit (2024-2029)
  • Table 517. Epilepsy Drugs Sales A staring spell , by Region unit (2024-2029)
  • Table 518. Epilepsy Drugs Sales Uncontrollable jerking movements of the arms and legs , by Region unit (2024-2029)
  • Table 519. Epilepsy Drugs Sales Loss of consciousness or awareness , by Region unit (2024-2029)
  • Table 520. Epilepsy Drugs Sales Psychic symptoms such as fear, anxiety or deja vu , by Region unit (2024-2029)
  • Table 521. South America Epilepsy Drugs Sales, by Country unit (2024-2029)
  • Table 522. South America Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 523. South America Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 524. South America Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 525. South America Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 526. South America Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 527. Brazil Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 528. Brazil Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 529. Brazil Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 530. Brazil Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 531. Brazil Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 532. Argentina Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 533. Argentina Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 534. Argentina Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 535. Argentina Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 536. Argentina Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 537. Rest of South America Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 538. Rest of South America Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 539. Rest of South America Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 540. Rest of South America Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 541. Rest of South America Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 542. Asia Pacific Epilepsy Drugs Sales, by Country unit (2024-2029)
  • Table 543. Asia Pacific Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 544. Asia Pacific Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 545. Asia Pacific Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 546. Asia Pacific Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 547. Asia Pacific Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 548. China Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 549. China Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 550. China Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 551. China Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 552. China Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 553. Japan Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 554. Japan Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 555. Japan Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 556. Japan Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 557. Japan Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 558. India Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 559. India Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 560. India Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 561. India Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 562. India Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 563. South Korea Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 564. South Korea Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 565. South Korea Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 566. South Korea Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 567. South Korea Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 568. Taiwan Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 569. Taiwan Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 570. Taiwan Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 571. Taiwan Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 572. Taiwan Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 573. Australia Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 574. Australia Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 575. Australia Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 576. Australia Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 577. Australia Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 578. Rest of Asia-Pacific Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 579. Rest of Asia-Pacific Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 580. Rest of Asia-Pacific Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 581. Rest of Asia-Pacific Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 582. Rest of Asia-Pacific Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 583. Europe Epilepsy Drugs Sales, by Country unit (2024-2029)
  • Table 584. Europe Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 585. Europe Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 586. Europe Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 587. Europe Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 588. Europe Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 589. Germany Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 590. Germany Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 591. Germany Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 592. Germany Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 593. Germany Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 594. France Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 595. France Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 596. France Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 597. France Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 598. France Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 599. Italy Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 600. Italy Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 601. Italy Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 602. Italy Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 603. Italy Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 604. United Kingdom Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 605. United Kingdom Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 606. United Kingdom Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 607. United Kingdom Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 608. United Kingdom Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 609. Netherlands Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 610. Netherlands Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 611. Netherlands Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 612. Netherlands Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 613. Netherlands Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 614. Rest of Europe Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 615. Rest of Europe Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 616. Rest of Europe Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 617. Rest of Europe Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 618. Rest of Europe Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 619. MEA Epilepsy Drugs Sales, by Country unit (2024-2029)
  • Table 620. MEA Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 621. MEA Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 622. MEA Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 623. MEA Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 624. MEA Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 625. Middle East Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 626. Middle East Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 627. Middle East Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 628. Middle East Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 629. Middle East Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 630. Africa Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 631. Africa Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 632. Africa Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 633. Africa Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 634. Africa Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 635. North America Epilepsy Drugs Sales, by Country unit (2024-2029)
  • Table 636. North America Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 637. North America Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 638. North America Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 639. North America Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 640. North America Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 641. United States Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 642. United States Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 643. United States Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 644. United States Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 645. United States Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 646. Canada Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 647. Canada Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 648. Canada Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 649. Canada Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 650. Canada Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 651. Mexico Epilepsy Drugs Sales, by Type unit (2024-2029)
  • Table 652. Mexico Epilepsy Drugs Sales, by Application unit (2024-2029)
  • Table 653. Mexico Epilepsy Drugs Sales, by Treatment Drugs unit (2024-2029)
  • Table 654. Mexico Epilepsy Drugs Sales, by End – User unit (2024-2029)
  • Table 655. Mexico Epilepsy Drugs Sales, by Symptoms unit (2024-2029)
  • Table 656. Epilepsy Drugs: by Type(USD/Units)
  • Table 657. Research Programs/Design for This Report
  • Table 658. Key Data Information from Secondary Sources
  • Table 659. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Epilepsy Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Epilepsy Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Epilepsy Drugs: by Treatment Drugs USD Million (2018-2023)
  • Figure 7. Global Epilepsy Drugs: by End – User USD Million (2018-2023)
  • Figure 8. Global Epilepsy Drugs: by Symptoms USD Million (2018-2023)
  • Figure 9. South America Epilepsy Drugs Share (%), by Country
  • Figure 10. Asia Pacific Epilepsy Drugs Share (%), by Country
  • Figure 11. Europe Epilepsy Drugs Share (%), by Country
  • Figure 12. MEA Epilepsy Drugs Share (%), by Country
  • Figure 13. North America Epilepsy Drugs Share (%), by Country
  • Figure 14. Global Epilepsy Drugs: by Type unit (2018-2023)
  • Figure 15. Global Epilepsy Drugs: by Application unit (2018-2023)
  • Figure 16. Global Epilepsy Drugs: by Treatment Drugs unit (2018-2023)
  • Figure 17. Global Epilepsy Drugs: by End – User unit (2018-2023)
  • Figure 18. Global Epilepsy Drugs: by Symptoms unit (2018-2023)
  • Figure 19. South America Epilepsy Drugs Share (%), by Country
  • Figure 20. Asia Pacific Epilepsy Drugs Share (%), by Country
  • Figure 21. Europe Epilepsy Drugs Share (%), by Country
  • Figure 22. MEA Epilepsy Drugs Share (%), by Country
  • Figure 23. North America Epilepsy Drugs Share (%), by Country
  • Figure 24. Global Epilepsy Drugs: by Type USD/Units (2018-2023)
  • Figure 25. Global Epilepsy Drugs share by Players 2023 (%)
  • Figure 26. Global Epilepsy Drugs share by Players (Top 3) 2023(%)
  • Figure 27. Global Epilepsy Drugs share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 33. UCB (Europe) Revenue, Net Income and Gross profit
  • Figure 34. UCB (Europe) Revenue: by Geography 2023
  • Figure 35. Cephalon, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Cephalon, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 39. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 40. Pfizer (United States) Revenue: by Geography 2023
  • Figure 41. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 43. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Sunovion Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 46. Sunovion Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 47. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 48. Bausch Health (Canada) Revenue: by Geography 2023
  • Figure 49. Global Epilepsy Drugs: by Type USD Million (2024-2029)
  • Figure 50. Global Epilepsy Drugs: by Application USD Million (2024-2029)
  • Figure 51. Global Epilepsy Drugs: by Treatment Drugs USD Million (2024-2029)
  • Figure 52. Global Epilepsy Drugs: by End – User USD Million (2024-2029)
  • Figure 53. Global Epilepsy Drugs: by Symptoms USD Million (2024-2029)
  • Figure 54. South America Epilepsy Drugs Share (%), by Country
  • Figure 55. Asia Pacific Epilepsy Drugs Share (%), by Country
  • Figure 56. Europe Epilepsy Drugs Share (%), by Country
  • Figure 57. MEA Epilepsy Drugs Share (%), by Country
  • Figure 58. North America Epilepsy Drugs Share (%), by Country
  • Figure 59. Global Epilepsy Drugs: by Type unit (2024-2029)
  • Figure 60. Global Epilepsy Drugs: by Application unit (2024-2029)
  • Figure 61. Global Epilepsy Drugs: by Treatment Drugs unit (2024-2029)
  • Figure 62. Global Epilepsy Drugs: by End – User unit (2024-2029)
  • Figure 63. Global Epilepsy Drugs: by Symptoms unit (2024-2029)
  • Figure 64. South America Epilepsy Drugs Share (%), by Country
  • Figure 65. Asia Pacific Epilepsy Drugs Share (%), by Country
  • Figure 66. Europe Epilepsy Drugs Share (%), by Country
  • Figure 67. MEA Epilepsy Drugs Share (%), by Country
  • Figure 68. North America Epilepsy Drugs Share (%), by Country
  • Figure 69. Global Epilepsy Drugs: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • UCB (Europe)
  • Cephalon, Inc. (United States)
  • Johnson & Johnson (United States)
  • Pfizer (United States)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (United States)
  • Sunovion Pharmaceuticals (United States)
  • Bausch Health (Canada)
Additional players considered in the study are as follows:
Sanofi S.A (France) , Shire (United States) , Eisai (Japan) , F. Hoffmann-La Roche (Switzerland)
Select User Access Type

Key Highlights of Report


Jan 2024 209 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Epilepsy Drugs Market Quantitative research analysis
Global Epilepsy Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Epilepsy Drugs market is expected to see a CAGR of % during projected year 2023 to 2029.
Top performing companies in the Global Epilepsy Drugs market are Abbott Laboratories (United States), GlaxoSmithKline Plc (United Kingdom), UCB (Europe), Cephalon, Inc. (United States), Johnson & Johnson (United States), Pfizer (United States), Novartis AG (Switzerland), AbbVie Inc. (United States), Sunovion Pharmaceuticals (United States) and Bausch Health (Canada), to name a few.
is dominating segment of Epilepsy Drugs Market in 2023.

Know More About Global Epilepsy Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Next Generation Antibody Therapeutics Comprehensive Study by Type (Antibody Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Prote...
$ 3650
Microsclerotherapy Treatment Comprehensive Study by Type (Sclerosants (Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others), Micro-Needles, Graduated Compression Hosiery Supports, Othe...
$ 3450
Halitosis Treatment Comprehensive Study by Type (Pathological, Non-pathological), Application (Lungs, Liver, Respiratory, Systemic, Gastrointestinal, Others), Diagnostic Tests (Gas chromatography, Ha...
$ 3750
Circulating Tumor Cells (CTC) Comprehensive Study by Type (Ex-Vivo Positive Selection, In-Vivo Positive Selection, Negative Selection, Microchips & Single Spiral Micro Channel), Application (Tumorige...
$ 3450
Sleep Disorder Therapeutics Comprehensive Study by Type (Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Others), Medical Devices) Players and ...
$ 3500
Shingles Treatments Comprehensive Study by Type (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Creams, Others), Route of Administration ...
$ 3450